You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

CLINICAL TRIALS PROFILE FOR DAROLUTAMIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DAROLUTAMIDE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02200614 ↗	Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer	Completed	Orion Corporation, Orion Pharma	Phase 3	2014-09-12	The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
NCT02200614 ↗	Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer	Completed	Bayer	Phase 3	2014-09-12	The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
NCT02799602 ↗	ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer	Active, not recruiting	Orion Corporation, Orion Pharma	Phase 3	2016-11-30	The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
NCT02799602 ↗	ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer	Active, not recruiting	Bayer	Phase 3	2016-11-30	The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
NCT03004534 ↗	A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide	Completed	Bayer	Early Phase 1	2017-09-05	The purpose of this study is to evaluate the effect of short-term treatment with darolutamide on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast cancer cells) and to evaluate its safety and the way it is tolerated by subjects. The intent is to study these changes in order to have a better understanding of the potential use of darolutamide for women with EBC, know which patients are likely or unlikely to respond to this treatment, and determine how darolutamide may be combined with other anti-cancer drugs.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DAROLUTAMIDE

Condition Name

Chart
Table

Condition Name for DAROLUTAMIDE
Intervention	Trials
Prostate Cancer	20
Metastatic Prostate Cancer	8
Prostatic Neoplasms	5
Prostate Adenocarcinoma	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DAROLUTAMIDE
Intervention	Trials
Prostatic Neoplasms	54
Adenocarcinoma	7
Hypersensitivity	6
Carcinoma	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DAROLUTAMIDE

Trials by Country

Map
Table

Trials by Country for DAROLUTAMIDE
Location	Trials
United States	260
Japan	80
Canada	55
Brazil	55
Germany	49
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DAROLUTAMIDE
Location	Trials
California	15
New York	12
Michigan	12
Pennsylvania	11
Ohio	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DAROLUTAMIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DAROLUTAMIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	16
Phase 2	28
[disabled in preview]	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DAROLUTAMIDE
Clinical Trial Phase	Trials
Recruiting	29
Not yet recruiting	21
Active, not recruiting	6
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DAROLUTAMIDE

Sponsor Name

Chart
Table

Sponsor Name for DAROLUTAMIDE
Sponsor	Trials
Bayer	30
National Cancer Institute (NCI)	6
Orion Corporation, Orion Pharma	4
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DAROLUTAMIDE
Sponsor	Trials
Other	59
Industry	53
NIH	6
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.